Sanderling Ventures
VC Fund
San Mateo, United States
Sanderling Ventures is an investment company that specializes in seed and early-stage investments. It also participates in later-stage financings. The firm focuses on new biomedical market opportunities, including emerging technology in the areas such as biotechnology, life sciences, therapeutics and pharmaceuticals, drug delivery, medical devices,and instrumentation; imaging and diagnostics, medical informatics, healthcare information technology; and health care services. It seeks to invest in United States and Canada.Sanderling Ventures was founded by Robert McNeil in 1979 and is headquartered in Sam Mateo, California.
- Total investments:
- 59
- Last investment:
- Lead investor:
- 22%
Last updated:
For AI agents: llms.txt
Industries Sanderling Ventures invests in
Stages Sanderling Ventures invests in
Countries Sanderling Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 24 (41%)
- Health Care 23 (39%)
- Medical 10 (17%)
- Pharmaceutical 8 (14%)
- Therapeutics 7 (12%)
Stage
- Series B 14 (24%)
- Series C 12 (20%)
- Series A 8 (14%)
- Series D 7 (12%)
- Funding Round 7 (12%)
Country
- United States 25 (42%)
- Canada 4 (7%)
- India 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Fred Middleton
Managing Director
|
Managing Director | Total investments: 8 | Find email | |
Timothy C. Mills
Managing Director
|
Managing Director | Total investments: 9 | Find email | |
Timothy Wollaeger
Managing Director
|
Managing Director | Total investments: 11 | Find email | |
Michael Dixon
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Paulette Taylor
General Counsel & Principal
|
General Counsel & Principal | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Glycomine
|
Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options. | $115M / Series C / Apr 16, 2025 | |
CalciMedica
|
CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $55M / Post-IPO Equity / Jan 22, 2024 | |
|
Glycomine
|
Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options. | $35M / Series B / Jun 23, 2021 | |
ViaCyte
|
ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeuticallyrelevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications. | Series D / Apr 22, 2021 | |
|
CalciMedica
|
CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $21M / Series D / Mar 11, 2021 | |
|
CalciMedica
|
CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $15M / Series C / May 22, 2020 | |
|
ViaCyte
|
ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeuticallyrelevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications. | $32.6M / Series D / Mar 20, 2020 | |
|
Glycomine
|
Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options. | $33M / Series B / Aug 07, 2019 | |
Metavention
|
Metavention develops medical devices to help with interventional therapies for Type 2 diabetes. | $65M / Series C / Jan 08, 2018 | |
SpecificiT Pharma
|
SpecificiT Pharma Inc., a privately held biopharmaceutical company focused on developing innovative personalized cancer immunotherapies.SpecificiT is developing cellular therapies for hematological cancers which to date, cannot be treated with chimeric antigen receptor modified T cells (CAR-T) therapies.SpecificiT’s unique approach iscentered on the use of Minor Histocompatability Antigens (“MiHAs”) which enable donor T-cells to be safely directed to eliminate cancer cells in a patient. | Seed / Sep 11, 2017 | |
| See all 59 investments → | |||
Co-Investors
Mayo Clinic Ventures
6 deals together
Intel Capital
4 deals together
PrairieGold Venture Partners
4 deals together
Qualcomm Ventures
4 deals together
Bain Capital Life Sciences
3 deals together
Chiesi Ventures
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Sanderling Ventures invest in?
Sanderling Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 59 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Sanderling Ventures?
Public channels for Sanderling Ventures include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sanderling Ventures?
The team at Sanderling Ventures includes Fred Middleton (Managing Director), Timothy C. Mills (Managing Director) and Timothy Wollaeger (Managing Director), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
